The injectable interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults; it was…
Med Lett Drugs Ther. 2025 Jun 9; 67(1730):92-4 doi:10.58347/tml.2025.1730c
The injectable interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults; it was approved earlier for treatment of ulcerative colitis (UC), plaque psoriasis, and psoriatic arthritis. The IL-23 antagonists risankizumab (Skyrizi) and mirikizumab (Omvoh) and the IL-12/23 antagonist ustekinumab ( Stelara , and biosimilars) are also approved for treatment of CD.
The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in…
Med Lett Drugs Ther. 2025 May 12; 67(1728):78-80 doi:10.58347/tml.2025.1728d
The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis. Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya) , are also approved for treatment of CD.
The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara…
Med Lett Drugs Ther. 2024 Jul 22; 66(1707):119 doi:10.58347/tml.2024.1707e
The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara (see Table 1). Wezlana is the first Stelara biosimilar to be approved in the US.
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have…
Med Lett Drugs Ther. 2023 Jul 10; 65(1680):105-12 doi:10.58347/tml.2023.1680a
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab…
Med Lett Drugs Ther. 2022 Dec 26; 64(1666):205-7
The injectable interleukin (IL)-23 antagonist risankizumab-rzaa ( Skyrizi – Abbvie) has been approved by the FDA for treatment of moderately to severely active Crohn's disease (CD) in adults. Risankizumab was approved earlier for treatment of plaque psoriasis and psoriatic arthritis.
An oral extended-release formulation of the corticosteroid budesonide ( Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending…
Med Lett Drugs Ther. 2020 Nov 2; 62(1610):176
An oral extended-release formulation of the corticosteroid budesonide ( Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending colon in patients ≥8 years old and for maintenance of remission for up to 3 months in adults. Ortikos is the second oral formulation of budesonide to be approved for this indication; Entocort EC , an ileal-release formulation, was the first. A third oral formulation of budesonide (Uceris) is approved for induction of remission in patients with mild to moderate active ulcerative colitis.
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection.…
Med Lett Drugs Ther. 2018 Jul 2; 60(1550):107-14
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
The FDA has approved infliximab-dyyb ( Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab (Remicade) . Infliximab-dyyb was approved in the European…
Med Lett Drugs Ther. 2017 Jan 30; 59(1513):23-5
The FDA has approved infliximab-dyyb ( Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab (Remicade) . Infliximab-dyyb was approved in the European Union (EU) in 2013 and in Canada in 2014. It is the second biosimilar to be approved by the FDA. Filgastrim-sndz (Zarxio) , a recombinant human granulocyte colony-stimulating factor, was the first.
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of…
Med Lett Drugs Ther. 2017 Jan 2; 59(1511):5-6
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.
The FDA has approved the subcutaneous IL-17A antagonist secukinumab ( Cosentyx - Novartis), which was first approved in 2015 for treatment of plaque psoriasis, for treatment of psoriatic arthritis and…
The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic…
Med Lett Drugs Ther. 2016 May 9; 58(1494):59-60
The FDA has approved ixekizumab ( Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ixekizumab is the second IL-17A antagonist to be approved for this indication in the US; secukinumab ( Cosentyx – Novartis) was the first.
The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC)…
Med Lett Drugs Ther. 2015 Nov 9; 57(1481):154
The FDA has approved a rectal foam formulation of the corticosteroid budesonide ( Uceris - Salix/Valeant) for induction of remission in patients with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Budesonide is also available as oral extended-release tablets (also branded as Uceris ) for use in patients with UC and as oral enteric-coated tablets ( Entocort EC , and generics) for treatment of Crohn's disease.
The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to,…
Med Lett Drugs Ther. 2014 Sep 15; 56(1451):86-8
The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri) , another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is…
Med Lett Drugs Ther. 2014 Aug 4; 56(1448):65-72
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol , Asacol HD , Lialda , and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine ( Azulfidine , and generics), balsalazide ( Colazal , and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa , and generics) and as a rectal suppository (Canasa) .
Three tumor necrosis factor (TNF) inhibitors – infliximab (Remicade) , adalimumab (Humira) , and certolizumab pegol (Cimzia) – are approved by the FDA for treatment of moderately to severely active…
Med Lett Drugs Ther. 2013 Dec 23; 55(1432):102-3
Three tumor necrosis factor (TNF) inhibitors – infliximab (Remicade) , adalimumab (Humira) , and certolizumab pegol (Cimzia) – are approved by the FDA for treatment of moderately to severely active Crohn’s disease in adults who have had an inadequate response to conventional therapy. Infliximab is also FDA-approved for the same indication in children ≥6 years old and for treatment of fistulas in adults. All 3 TNF inhibitors have been shown to reduce the signs and symptoms of Crohn's disease in clinical trials. They have been associated with adverse effects such as tuberculosis, other serious infections, and lymphoma, and they are expensive.
The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel syndrome (SBS) in adults who are dependent on…
Med Lett Drugs Ther. 2013 Apr 15; 55(1414):29-30
The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel syndrome (SBS) in adults who are dependent on parenteral support.
The FDA has approved a new extended-release formulation of the corticosteroid budesonide ( Uceris – Santarus) for induction of remission in patients with mild to moderate ulcerative colitis.
Med Lett Drugs Ther. 2013 Mar 18; 55(1412):23
The FDA has approved a new extended-release formulation of the corticosteroid budesonide ( Uceris – Santarus) for induction of remission in patients with mild to moderate ulcerative colitis.
Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of…
Treat Guidel Med Lett. 2012 Mar; 10(115):19-28
Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of Gastroenterology.
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is…
Treat Guidel Med Lett. 2009 Sep; 7(85):65-74
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.
The FDA has approved the marketing of certolizumab pegol ( Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is…
Med Lett Drugs Ther. 2008 Oct 20; 50(1297):81-2
The FDA has approved the marketing of certolizumab pegol ( Cimzia - UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn's disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement:…
Med Lett Drugs Ther. 2008 Jun 2; 50(1287):44
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "post-marketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is recognized as an important predictor of severe liver injury that may lead to [emphasis added] death or the need for a liver transplant in some patients." Also, in the last sentence of the Conclusion, we should have said: "Because of the risk of serious hepatic toxicity and the rare but even more serious risk of developing progressive multifocal leukoencephalopathy, it should be used only in patients who have not responded to other drugs, including a TNF inhibitor." The italicized words should be substituted for "it is FDA-approved for use." Download: U.S. English
Natalizumab ( Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors…
Med Lett Drugs Ther. 2008 May 5; 50(1285):34-6
Natalizumab ( Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML). It is now available for treatment of both MS and CD through a restricted distribution program.
( Vol. 49, p. 66, August 13, 2007 ) A reader has pointed out that Saccharomyces boulardii is not a separate species, but a strain of Saccharomyces cerevisiae . S. cerevisiae (including S. boulardii ) has been…
Med Lett Drugs Ther. 2007 Dec 3; 49(1275):100
( Vol. 49, p. 66, August 13, 2007 ) A reader has pointed out that Saccharomyces boulardii is not a separate species, but a strain of Saccharomyces cerevisiae . S. cerevisiae (including S. boulardii ) has been reported to cause systemic infection after oral ingestion in both immunocompromised patients and healthy hosts (MJ McCullough et al. J Clin Microbiol 1998; 36:2613).
Probiotics are live, nonpathogenic microorganisms (usually bacteria or yeasts) that have been used for centuries for their potential health benefits. They are currently marketed for prevention and treatment of…
Med Lett Drugs Ther. 2007 Aug 13; 49(1267):66-8
Probiotics are live, nonpathogenic microorganisms (usually bacteria or yeasts) that have been used for centuries for their potential health benefits. They are currently marketed for prevention and treatment of a variety of disorders, including diarrhea, irritable bowel syndrome and inflammatory bowel disease.